PMID- 33215437
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 24
IP  - 21
DP  - 2020 Nov
TI  - MiR-133b inhibits MPP+-induced apoptosis in Parkinson's disease model by 
      inhibiting the ERK1/2 signaling pathway.
PG  - 11192-11198
LID - 23607 [pii]
LID - 10.26355/eurrev_202011_23607 [doi]
AB  - OBJECTIVE: The aim of this study was to explore the effect of micro ribonucleic 
      acid (miR)-133b on 1-methyl-4-phenylpyridinium ion (MPP+)-induced apoptosis in 
      the Parkinson's disease (PD) model. MATERIALS AND METHODS: PC12 cells were 
      induced by different concentrations of MPP+ to establish the PD cell model. 
      Subsequently, the survival rate of PC12 cells was detected using Cell Counting 
      Kit-8 (CCK-8) assay. Quantitative Reverse Transcription-Polymerase Chain Reaction 
      (qRT-PCR) was used to detect the expression of miR-133b in the PD model induced 
      by different concentrations of MPP+. Next, PC12 cells were transfected with 
      miR-133b mimic and miR-negative control (NC), and divided into MPP+ group, MPP+ + 
      miR-NC group and MPP+ + miR-133b mimic group. Transfection efficiency was 
      verified using qRT-PCR. The apoptosis of cells was detected using terminal 
      deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. 
      Moreover, the expressions of extracellular signal-regulated kinase 1/2 (ERK1/2) 
      and phosphorylated (p)-ERK1/2 were determined using Western blotting. RESULTS: 
      After MPP+ treatment, the survival rate of PC12 cells significantly declined 
      (p<0.05). MPP+ exhibited toxicity against PC12 cells in a concentration-dependent 
      manner. Meanwhile, cell survival rate decreased remarkably with the increase of 
      MPP+ concentration (p<0.05). With increased concentration of MPP+, the expression 
      of miR-133b in the PD cell model declined significantly (p<0.05). The apoptosis 
      of PC12 cells was remarkably inhibited by overexpression of miR-133b in the PD 
      cell model (p<0.05). In addition, the protein expression of p-ERK1/2 in PC12 
      cells was notably reduced after overexpression of miR-133b in the PD cell model 
      (p<0.05). CONCLUSIONS: MiR-133b is lowly expressed in the PD cell model. 
      Furthermore, overexpression of miR-133b inhibits cell apoptosis in the PD cell 
      model by regulating the ERK1/2 signaling pathway.
FAU - Dong, L-G
AU  - Dong LG
AD  - Department of Neurology, the Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China. cuiguiyun-js@163.com.
FAU - Lu, F-F
AU  - Lu FF
FAU - Zu, J
AU  - Zu J
FAU - Zhang, W
AU  - Zhang W
FAU - Xu, C-Y
AU  - Xu CY
FAU - Jin, G-L
AU  - Jin GL
FAU - Yang, X-X
AU  - Yang XX
FAU - Xiao, Q-H
AU  - Xiao QH
FAU - Cui, C-C
AU  - Cui CC
FAU - Xu, R
AU  - Xu R
FAU - Zhou, S
AU  - Zhou S
FAU - Zhu, J-N
AU  - Zhu JN
FAU - Shen, T
AU  - Shen T
FAU - Cui, G-Y
AU  - Cui GY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (MIRN133 microRNA, rat)
RN  - 0 (MicroRNAs)
RN  - EC 2.7.11.24 (Mapk1 protein, rat)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
RN  - R865A5OY8J (1-Methyl-4-phenylpyridinium)
SB  - IM
MH  - 1-Methyl-4-phenylpyridinium/antagonists & inhibitors/pharmacology
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - *Disease Models, Animal
MH  - MicroRNAs/*metabolism
MH  - Mitogen-Activated Protein Kinase 1/genetics/*metabolism
MH  - Mitogen-Activated Protein Kinase 3/genetics/*metabolism
MH  - PC12 Cells
MH  - Parkinson Disease/*drug therapy/metabolism/pathology
MH  - Rats
MH  - Signal Transduction/drug effects
EDAT- 2020/11/21 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/11/20 05:52
PHST- 2020/11/20 05:52 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - 23607 [pii]
AID - 10.26355/eurrev_202011_23607 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11192-11198. doi: 
      10.26355/eurrev_202011_23607.